Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1432-2277.2010.01129.xDOI Listing

Publication Analysis

Top Keywords

kidney transplantation
4
transplantation patient
4
patient congenital
4
congenital vena
4
vena cava
4
cava vena
4
vena iliaca
4
iliaca communis
4
communis hypoplasia
4
vena
2

Similar Publications

Background: 'Life Years from Transplant' (LYFT) is a measure of the predicted difference between the expected lifespan with and without a kidney transplant. The metric was originally proposed in 1999; since then, demographics of the kidney transplant candidate population have materially changed.

Methods: Using contemporary SRTR data, we propose more sophisticated methods for estimating LYFT with a focus on older kidney transplant candidates, a growing sector of the current candidate pool.

View Article and Find Full Text PDF

Long-term, immunosuppression-free allograft survival has been induced in human and nonhuman primate (NHP) kidney recipients after nonmyeloablative conditioning and donor bone marrow transplantation (DBMT), resulting in transient mixed hematopoietic chimerism. However, the same strategy has consistently failed in NHP heart transplant recipients. Here, we investigated whether long-term heart allograft survival could be achieved by cotransplanting kidneys from the same donor.

View Article and Find Full Text PDF

De novo proliferative glomerulonephritis with monoclonal IgG deposits in an adolescent kidney transplant recipient.

Pediatr Nephrol

January 2025

Department of Pediatrics, University of California, San Diego, 3020 Children's Way MC 5173, San Diego, CA, 92123, USA.

Proliferative Glomerulonephritis with Monoclonal IgG Deposits (PGNMID) is a glomerular disease characterized by membranoproliferative and mesangioproliferative lesions, with granular capillary wall monoclonal IgG positivity and immunoglobulin light chain restriction. Most commonly a disease of older adults, we present the case of an 18-year-old patient who developed de novo PGNMID in a kidney allograft three years after kidney transplantation. There was minimal proteinuria and no serum paraproteinemia was detected, so the patient was managed conservatively.

View Article and Find Full Text PDF

Efficacy of complement inhibition with pegcetacoplan in children with C3 glomerulopathy.

Pediatr Nephrol

January 2025

Center for HUS Prevention, Control and Management at the Pediatric Nephrology, Dialysis and Transplantation Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Background: C3 glomerulopathy (C3G) is a rare kidney disease due to a dysregulation of the alternative complement pathway, orphan of specific treatment. Pegcetacoplan is an inhibitor of the third complement component C3, currently on a phase III registration protocol in C3G. Here we describe our experience with the off-label use of pegcetacoplan in pediatric patients with C3G.

View Article and Find Full Text PDF

Cell cycle arrest biomarkers for early diagnosis of acute kidney injury after liver transplantation: A prospective cohort study.

Eur J Anaesthesiol

January 2025

From the Department of Anaesthesia, King's College Hospital NHS Foundation Trust, London, UK (BM, GK), Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK (KM, MM), Department of Critical Care, Guy's & St Thomas' NHS Foundation Trust, London, UK (MO), Department of Critical Care, University of Pittsburgh, USA (JAK), School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, UK (GK).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!